Treating radiation-induced xerostomia

Researchers have found that a novel treatment may be effective in patients with radiation-induced xerostomia.

A majority of new oropharyngeal cancer cases are caused by human papillomavirus infections, the incidence of which has been gradually increasing, according to a report from RDH magazine. Although radiation therapy has been effective at treating patients with HPV-positive oropharyngeal cancer, these patients may have a higher risk of subsequently developing xerostomia. The condition can reduce the ability to swallow, speak and taste and heighten the risk of dental caries.

In a phase I clinical trial, the researchers examined the potential benefit of regenerative therapy using stromal cells to improve salivary gland function in patients with radiation-induced xerostomia. The researchers extracted stromal cells from the patients’ bone marrow treated with interferon gamma and injected them into their salivary glands.

After a follow-up of two years, the patients demonstrated improved natural saliva production and quality of life.

The researchers hope their novel treatment strategy can someday become the standard of care in patients with radiation-induced xerostomia.

Read more: RDH magazine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.